Gilead's Request To Revoke Remdesivir Orphan Designation Reflects Pandemic Pressures
Executive Summary
Two days after US FDA granted remdesivir orphan status for treatment of COVID-19, Gilead told the agency it is unnecessary. EMA says it would not grant orphan drug designation to a COVID-19 treatment.
You may also be interested in...
Remdesivir’s Path To Orphan Designation Could Be Exploited By Others, Experts Warn
Congress should give FDA more flexibility to administer orphan designations, such as the ability to revoke designations later if the disease prevalence grows beyond the rare disease threshold.
Orphan Exclusivity: Rarely Used, But Well-Known, Loophole Would Be Closed By House Legislation
US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.
Pediatric Study Plans For Coronavirus Therapies To Get Trans-Atlantic Streamlining
EMA and US FDA offer sponsors help in completing their pediatric study plan templates and identifying areas of overlap between the two agencies requirements.